• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VELIPARIB Drug Record

  • Summary
  • Interactions
  • Claims
  • VELIPARIB chembl:CHEMBL506871 Antineoplastic

    Alternate Names:

    ABT-888
    VELIPARIB
    PARP-1 INHIBITOR ABT-888
    ABT 888
    2-[(R)-2-METHYLPYRROLIDIN-2-YL]-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
    (2R)-2-(7-CARBAMOYL-1H-BENZIMIDAZOL-2-YL)-2-METHYLPYRROLIDINIUM
    2-((2R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
    pubchem.compound:11960529
    drugbank:07232
    chembl:CHEMBL506871
    chemidplus:912444-00-9

    Drug Info:

    Pharmaceutical Developer Active Biochem
    Source Reported Drug Name(s) Veliparib/ABT-888
    Drug Class PARP Inhibitor
    Drug Class Small molecule inhibitor
    (7 More Sources)

    Publications:

    Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
    Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
    LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
    Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
    O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
    Patel et al., 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells., Proc. Natl. Acad. Sci. U.S.A.
    Subhash et al., 2016, ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis., Mol. Cancer Ther.
    Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
    Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
  • VELIPARIB   PARP2

    Interaction Score: 6.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction PARP 1, 2 and 3 inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    10592235


    Sources:
    TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

  • VELIPARIB   PARP1

    Interaction Score: 3.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction PARP 1, 2 and 3 inhibitor
    Reported Cancer Type Prostate

    PMIDs:
    10592235


    Sources:
    TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

  • VELIPARIB   STAG2

    Interaction Score: 2.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    24356817 21852505


    Sources:
    JAX-CKB

  • VELIPARIB   BRCA2

    Interaction Score: 1.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type prostate cancer
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    29338080 25589624 26842236 26801247


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • VELIPARIB   PARP3

    Interaction Score: 1.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction PARP 1, 2 and 3 inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • VELIPARIB   ATR

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • VELIPARIB   BRCA1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Veliparib + Carboplatin
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    25589624 26801247 26842236 25824335 29338080


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • VELIPARIB   ATM

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type stomach cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    21300883 27638859


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • VELIPARIB   MET

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • VELIPARIB   PTEN

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + Veliparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • MyCancerGenome: VELIPARIB

    • Version: 20-Jun-2017

    Alternate Names:
    ABT-888 Development Name
    VELIPARIB Generic Name

    Drug Info:
    Drug Class Small molecule inhibitor

    Publications:

  • CancerCommons: ABT-888

    • Version: 25-July-2013

    Alternate Names:
    2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide PubChem Drug Name
    11960529 PubChem Drug ID
    Veliparib Drug Trade Name

    Drug Info:
    Drug Class PARP Inhibitor
    Source Reported Drug Name(s) Veliparib/ABT-888
    Pharmaceutical Developer Active Biochem

    Publications:

  • JAX-CKB: Veliparib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
    Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
    Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.

  • CIViC: VELIPARIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer

  • TTD: ABT-888

    • Version: 2020.06.01

    Alternate Names:
    D0Q7UD TTD Drug ID

    Drug Info:

    Publications:

  • TALC: VELIPARIB

    • Version: 12-May-2016

    Alternate Names:
    VELIPARIB Primary Drug Name
    VELIPARIB Drug Generic Name
    ABT-888 Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL506871

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: VELIPARIB

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: VELIPARIB

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: VELIPARIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL506871

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21